Equillium Advances EQ504 to Mid-2026 Phase 1 Trial for Ulcerative Colitis
Equillium advances EQ504 into a mid-2026 Phase 1 trial for ulcerative colitis using its multi-cytokine platform to selectively target cytokines and potentially improve efficacy and safety over broad-spectrum inhibitors. Oral EQ302, an IL-15/IL-21 inhibitor for celiac disease, remains in early discovery with partnering discussions underway.
1. Multi-Cytokine Platform Overview
Equillium’s proprietary multi-cytokine platform enables selective inhibition of key inflammatory mediators rather than broad-spectrum targets like JAK/STAT. This approach is designed to reduce off-target immunosuppression while maximizing therapeutic efficacy by modulating multiple cytokines involved in autoimmune and inflammatory disorders.
2. EQ504 Phase 1 Trial Timeline
The company has slated initiation of a first-in-human Phase 1 trial for EQ504, a potent aryl hydrocarbon receptor modulator, in ulcerative colitis by mid-2026. EQ504 is engineered for targeted local delivery via enteric coating to treat gastrointestinal inflammation without systemic immunosuppression.
3. EQ302 Early Discovery and Partnering Prospects
EQ302, an oral inhibitor of IL-15 and IL-21 for celiac disease, is in preclinical discovery and positioned for external partnership. Management views collaboration as a catalyst to accelerate development and leverage external expertise while preserving internal focus on EQ504.